about
Pharmacovigilance and pharmacogenetic discussions at WorldPharma 2010.Drug safety advances from ICPE 2010.Latest drug safety alerts from the 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.Efficacy and safety of adalimumab in Crohn's diseaseWhat are the therapeutic advances in gastroenterology? opinions from world experts.What are the Therapeutic Advances in Neurology? Opinions from World Experts.Targeting precision medicine toxicity: recent developments.Latest advances in medical oncology: highlights from Milan ESMO 2010 annual congress.Pathways and biomarkers in breast cancer: latest evidence.Osteoporosis therapeutics: recent developments at ASBMRLatest therapeutic advances in musculoskeletal disease from the ACR 2015 annual conference.Targeted therapies in medical oncology: successes, failures and next steps.An evaluation of eptacog alfa in nonhaemophiliac conditions.Accuracy of packaging of dose administration aids in regional aged care facilities in the Hunter area of New South Wales.European Society for Medical Oncology Copenhagen update: potential practice-changing findingsLooking at the causes of, and possible treatments for, psychiatric diseases: gene-environment interactions, circadian rhythms and neuronal dysfunction.Highlights of the 2nd European lung cancer conference.Liaison between public hospital staff and the pharmaceutical industry: guidance from the NSW Therapeutic Advisory Group.Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil.The involvement of platelets and the coronary vasculature in collagen-induced sudden death in rabbitsThe effect of arachidonic acid metabolism on intravascular platelet aggregation in ratsComparison of the actions of 11.9 epoxymethano PGH2 and 9.11 azo PGH2 on rat aorta and stomach strip preparationsTherapeutic management of hyperlipoproteinemia (a)
P50
Q33949193-E4FFA337-DE0C-41BF-9F4E-24D2D83DB533Q33949233-BE2D7B8B-CEE8-4AD8-8A4B-5ECED6CA42A9Q33949336-77B3A699-4DFA-4A97-94D1-7819465FC47AQ34408865-AE0DEBCC-E38F-4177-8C39-AFA536EE9732Q34408900-9B42466F-6350-4B92-8EEF-168DD6D3448AQ34409057-E334C9C0-F13F-4631-A18C-084CFAEF4EDAQ35019470-862B4DAB-E6DB-44C1-A81A-DE20F16D81C5Q35076336-52179BB1-A3BD-4186-9540-71349C25AF3BQ36061181-6CB379DC-1980-45B3-AE62-010E24A75176Q36448678-72B65EFA-367F-49B0-9BC0-784783586DD7Q36448681-B814BAA4-9F19-4F08-8B7B-7ABCF2C03B63Q36515537-8C694E7E-7C37-4E5B-88C1-B37714F4CC6FQ37235606-926916BB-72CB-4357-9814-F3BF5FF09D5BQ39837162-79316726-A798-41F0-B3AB-0EF8D7097512Q42323113-4D86390A-783A-4010-9875-B5F6E9C1FF46Q42385085-50D29B07-C149-405A-8984-0EBC4AB92202Q42779355-3D286EF9-BEA7-4122-9F3D-FDA988337775Q53107606-B9AE9359-52C6-436E-A394-593AD7A5B1A2Q55025652-836F75CA-A3F4-4E9F-830D-3ADD4DF32A43Q70098494-E4098435-8FD1-460D-B8DD-0C431F8E729BQ70508656-D9D27AE8-1906-4822-9CEF-92D6F1742F85Q71309648-9B73D8F8-C96F-4A64-977B-4F59CC1E8AD9Q90291071-6E66073F-401E-43F9-AF92-941C802C54A6
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gordon Mallarkey
@ast
Gordon Mallarkey
@en
Gordon Mallarkey
@es
Gordon Mallarkey
@nl
Gordon Mallarkey
@sl
type
label
Gordon Mallarkey
@ast
Gordon Mallarkey
@en
Gordon Mallarkey
@es
Gordon Mallarkey
@nl
Gordon Mallarkey
@sl
prefLabel
Gordon Mallarkey
@ast
Gordon Mallarkey
@en
Gordon Mallarkey
@es
Gordon Mallarkey
@nl
Gordon Mallarkey
@sl
P106
P1153
6701535281
P21
P31
P496
0000-0002-0042-8344